UNSPSC 51434922: Chlorthalidone/clonidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434922 Chlorthalidone/clonidine, a Commodity code, encompasses individual pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and institutional healthcare operations. State and local buyers under this code source specific medications—often through emergency services procurement, cooperative purchasing alliances, and pharmacy benefit programs—with firm pricing, expiration-date warranties, delivery guarantees, and compliance with FDA, cGMP, and DSCSA standards. Recent solicitations show fire rescue departments, state health agencies, and multistate purchasing cooperatives buying individual medication line items and establishing framework agreements with manufacturers and wholesalers. Issuing bodies include municipal fire departments (City of Tampa), state health commissions (Texas Health and Human Services Commission), and cooperative purchasing organizations spanning multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Vendors typically must maintain distributor relationships, meet insurance and liability thresholds, provide comprehensive Safety Data Sheets and accessibility documentation, and accept performance penalties for late reporting or missed onboarding deadlines.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's IFB for Advanced Life Support Medications (26P00188, due April 8, 2026, estimated $40,000) specified four medication line items for Tampa Fire Rescue with nine-month minimum expiration dates and ten-day delivery windows, carrying a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to explore vendor capacity for direct-to-manufacturer pharmacy initiatives, signaling the state's interest in restructuring pharmaceutical procurement outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with pricing weighted at 75 percent and a two-year contract term beginning July 1, 2026.